TPST

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation in vivo CAR-T cell therapies for autoimmune and oncology indications. The company utilizes a dual-target CD19/BCMA CAR structure and a proprietary CD7-targeted mRNA lipid nanoparticle delivery platform to enhance T-cell reach and intracellular delivery. Its lead candidate, TPST-4003, is aimed at treating myasthenia gravis and multiple sclerosis, while TPST-2003 targets relapsed/refractory multiple myeloma and is in collaboration with Novatim Immune Therapeutics for development in China.